FDA Commissioner Marty Makary Resigns Amid White House Pressure Over E-Cigarette Approval

FDA Commissioner Marty Makary Resigns After White House Approval to Fire Him

Marty Makary, Commissioner of the U.S. Food and Drug Administration (FDA), resigned from his position on Tuesday, December 10, 2024. The resignation came just days after reports surfaced on Friday, December 6, 2024, that the White House had approved plans to dismiss him.

Trump Confirms Resignation via Social Media

Former President Donald Trump confirmed Makary’s resignation on social media. He shared an image that appeared to show Makary’s resignation letter sent via text message. The message read:

Dr. President Trump,
Please accept my resignation, effective today.

In a separate social media post, Trump praised Makary’s work at the FDA, stating:

"Marty Makary has done a great job at the FDA. He is a hard worker, who was respected by all, and will go on to have an outstanding career in Medicine."

Background on the Resignation

The timing of Makary’s resignation follows reports that the White House had approved plans to remove him from his role as FDA Commissioner. The exact reasons behind the planned dismissal were not disclosed in public statements.

Makary’s resignation marks a significant shift in leadership at the FDA, an agency responsible for regulating food, drugs, and medical products in the United States.

Reactions and Implications

The resignation has sparked discussions about the independence of federal agencies under political pressure. Makary, a physician and public health advocate, had previously been a vocal critic of certain regulatory policies, including those related to e-cigarettes and tobacco products.

As of the time of reporting, no official successor to Makary has been named. The FDA will continue operations under interim leadership until a permanent replacement is confirmed by the Senate.

About Marty Makary

Marty Makary is a surgeon and professor at Johns Hopkins University. He has been a prominent figure in public health policy, known for his research on healthcare quality, patient safety, and medical innovation. Before his role at the FDA, he served in various advisory capacities in the healthcare sector.